Company / Financials
Integra Lifesciences Holdings Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.6B
FY2025 · +1.5% YoY
Net Income
-$516.5M
FY2025 · -7337.7% YoY
Profit Margin
-31.6%
FY2025 · net income / revenue
ROE
-49.5%
FY2025 · return on equity
Total Assets
$3.6B
FY2025
Total Debt
$726.6M
0.70x debt/equity
Equity
$1.0B
FY2025
ROA
-14.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.6B+1.5% YoYNet Income HistoryProfit after all expenses and taxes-$516.5M-7337.7% YoYGross Profit HistoryRevenue minus cost of goods sold$851.0MCost of Revenue HistoryDirect costs of producing goods and services sold$803.6M+10.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$493.4M-1836.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$699.7M-2.4% YoYR&D Expense HistoryResearch and development spending$99.0M-14.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$51.4MIncome Tax HistoryTotal income tax expense-$47.0M-316.4% YoYEPS (Basic) HistoryBasic earnings per share$0.85-61.0% YoY